
Omeros (OMER): YARTEMLEA Launch Drives a Buy Case
Omeros is transitioning from a development story to a commercial biotech as YARTEMLEA ramps quickly, but the stock still carries meaningful balance-sheet and execution risk. The launch momentum and improving cash flow support a Buy rating despite volatile GAAP results.



